Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Senti Biosciences (SNTI) EBIT Margin (2021 - 2023)

Senti Biosciences (SNTI) has 3 years of EBIT Margin data on record, last reported at 5615.02% in Q4 2023.

  • For Q4 2023, EBIT Margin rose 3407942.0% year-over-year to 5615.02%; the TTM value through Sep 2024 reached 19090.09%, up 2310988.0%, while the annual FY2023 figure was 4687.92%, 323939.0% down from the prior year.
  • EBIT Margin reached 5615.02% in Q4 2023 per SNTI's latest filing, up from 12981.07% in the prior quarter.
  • Across five years, EBIT Margin topped out at 5615.02% in Q4 2023 and bottomed at 28464.41% in Q4 2022.
  • Average EBIT Margin over 3 years is 3994.77%, with a median of 1065.04% recorded in 2022.
  • Peak YoY movement for EBIT Margin: tumbled -2808278bps in 2022, then surged 3407942bps in 2023.
  • A 3-year view of EBIT Margin shows it stood at 381.63% in 2021, then plummeted by -7359bps to 28464.41% in 2022, then soared by 120bps to 5615.02% in 2023.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 5615.02% in Q4 2023, 12981.07% in Q3 2023, and 2095.52% in Q2 2023.